These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38722225)

  • 21. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
    Ataseven B; Lederer B; Blohmer JU; Denkert C; Gerber B; Heil J; Kühn T; Kümmel S; Rezai M; Loibl S; von Minckwitz G
    Ann Surg Oncol; 2015 Apr; 22(4):1118-27. PubMed ID: 25297900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
    Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude.
    Debled M; MacGrogan G; Breton-Callu C; Ferron S; Hurtevent G; Fournier M; Bourdarias L; Bonnefoi H; Mauriac L; Tunon de Lara C
    Eur J Cancer; 2015 Apr; 51(6):697-704. PubMed ID: 25704790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
    Berg T; Jensen MB; Jakobsen EH; Al-Rawi S; Kenholm J; Andersson M
    Breast; 2020 Dec; 54():242-247. PubMed ID: 33186804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
    Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
    JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic alterations in breast cancer associated with neoadjuvant chemotherapy: A comparison with baseline rates of change.
    Hariri N; Roma AA; Hasteh F; Walavalkar V; Fadare O
    Ann Diagn Pathol; 2017 Dec; 31():14-19. PubMed ID: 29146052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
    Fernandez-Gonzalez S; Falo C; Pla MJ; Campos M; Ortega-Exposito C; Ortega R; Vicente M; Petit A; Bosch-Schips J; Bajen MT; Reyes G; Martínez E; González-Viguera J; Peñafiel J; Stradella A; Pernas S; Ponce J; Garcia-Tejedor A
    Breast Cancer Res Treat; 2024 Jul; 206(1):131-141. PubMed ID: 38635082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.
    Xiong Y; Liang LZ; Cao LP; Min Z; Liu JH
    Gynecol Oncol; 2011 Oct; 123(1):99-104. PubMed ID: 21741694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    Firouzabadi D; Dehghanian A; Rezvani A; Mahmoudi L; Talei A
    BMC Cancer; 2021 Jan; 21(1):47. PubMed ID: 33430808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM; Blume JD; Bernreuter WK; Pisano ED; Rosen MA; Morris EA; Weatherall PT; Lehman CD; Newstead GM; Polin S; Marques HS; Esserman LJ; Schnall MD;
    Radiology; 2012 Jun; 263(3):663-72. PubMed ID: 22623692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
    JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.
    Parikh J; Selmi M; Charles-Edwards G; Glendenning J; Ganeshan B; Verma H; Mansi J; Harries M; Tutt A; Goh V
    Radiology; 2014 Jul; 272(1):100-12. PubMed ID: 24654970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
    Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early progression of breast cancer during neoadjuvant chemotherapy may predict poorer prognoses.
    Myller S; Ipatti P; Jääskeläinen A; Haapasaari KM; Jukkola A; Karihtala P
    Acta Oncol; 2020 Sep; 59(9):1036-1042. PubMed ID: 32394761
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(5):1989-92. PubMed ID: 24716923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.